Elvucitabine
- Generic Name
- Elvucitabine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H10FN3O3
- CAS Number
- 181785-84-2
- Unique Ingredient Identifier
- M09BUF90C0
- Indication
Investigated for use/treatment in hepatitis (viral, B) and HIV infection.
- Associated Conditions
- -
- Associated Therapies
- -
An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT00675844
- Locations
- 🇺🇸
Clinical Trial Site, Dallas, Texas, United States
Safety Study of Elvucitabine in HIV-1 Subjects
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2009-02-04
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 5
- Registration Number
- NCT00405249
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT00380159
- Locations
- 🇪🇸
Clinical Trial Site, Madrid, Spain
Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT00350272
- Locations
- 🇵🇷
Clinical Trial Site, San Juan, Puerto Rico
Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00312039
- Locations
- 🇺🇸
Clinical Trial Site, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath